This is the first report to show an impaired IFN-α response via TLR3/RIG-I and TLR7/8 in T2DM patients prescribed metformin, whereas only via TLR7/8 in those prescribed glibenclamide. The gene discussed is TLR3; the disease is type 2 diabetes mellitus.